-
Promising Phase 2 Results: A New Hope for Advanced NSCLC Treatment
NASDAQ: $BNTX A Breakthrough in Lung Cancer Research In a significant development for oncology, BioNTech and Bristol Myers Squibb have released encouraging global Phase 2 clinical trial data for their investigational bispecific antibody, pumitamig. The study focused on patients with advanced non-small cell lung cancer (NSCLC) who have progressed following standard-of-care therapies. Understanding the Clinical…
-
New Data on Lilly’s Investigational Treatment Olomorasib at ESMO 2026 Show Durable First-Line Activity in KRAS G12C-Mutant Non-Small Cell Lung Cancer
NYSE: $LLY INDIANAPOLIS, Oct. 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology… Source: Read More
-
A New Hope in Lung Cancer: FDA Grants Fast Track Designation for TRE-515 Combination
Accelerating Progress in NSCLC Treatment The landscape of lung cancer treatment continues to evolve, with the FDA recently granting Fast Track designation to the investigational therapeutic combination involving TRE-515. This designation is a significant milestone for patients fighting non-small cell lung cancer (NSCLC), particularly those whose tumors harbor specific genetic mutations. The Role of KRAS…
-
A New Milestone in Oncology: FDA Grants Accelerated Approval to Hyrnuo (sevabertinib)
OTCMKTS: $BAYRY A Breakthrough for NSCLC Patients The landscape of cancer treatment continues to evolve with the recent news that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Hyrnuo (sevabertinib). This development marks a significant shift for patients diagnosed with non-small cell lung cancer (NSCLC). What is Hyrnuo? Hyrnuo represents the…
-
A Major Milestone: AbbVie’s Telisotuzumab Vedotin Secures Two FDA Breakthrough Therapy Designations
NYSE: $ABBV Transforming Care for NSCLC Patients In a significant step forward for oncology, AbbVie has announced that the U.S. Food and Drug Administration (FDA) has granted two Breakthrough Therapy Designations (BTD) to their investigational therapy, telisotuzumab vedotin (Teliso-V). This recognition highlights the potential of this treatment to address the urgent needs of patients living…
-
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
NASDAQ: $CGEM CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) — Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases… Source: Read More
-
A New Frontier in Lung Cancer Treatment: HARMONI Phase III Results for Ivonescimab
NASDAQ: $SMMT A Breakthrough in Oncology Recent findings published in The Lancet have shed light on the promising results of the HARMONI Phase III clinical trial. The study evaluates the efficacy and safety of ivonescimab, a novel bispecific antibody, when combined with chemotherapy for the treatment of patients with locally advanced or metastatic non-squamous non-small…
-
Advancing Lung Cancer Treatment: Insights from the EVOLVE-Lung02 Phase III Trial
A New Frontier in Non-Small Cell Lung Cancer Therapy Recent developments in oncology have brought forward promising data from the EVOLVE-Lung02 Phase III clinical trial. This study is evaluating the efficacy of volrustomig, a novel bispecific antibody, when combined with standard chemotherapy for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). Understanding the Research…